The DOE Isotope Program: Introduction and Project Perspective

Khianne Jackson

Federal Program Manager

Office of Isotope R&D and Production, SC-IRP


DOE Isotope Program, DOE IP 1



- Organization
- Mission and Authority
- Isotope Landscape
- DOE IP Growth
- Isotope Priorities
- Projects and Initiatives
 - SIPRC Stable Isotope Production and Research Center, ORNL
 - CARP Clinical Alpha Radionuclide Facility, BNL
 - RPF Radioisotope Processing Facility, ORNL




Office of Science Organization Chart





Faces of the Office of Isotope R&D and Production



Open Positions: Chief of Staff, Program Managers, Program Analyst, and Detailees




DOE IP - Current Organization

** Vacant Position (Acting)

PM – Program Manager

Succession Planning in Progress






National Isotope Development Center

The NIDC (Oak Ridge National Laboratory) is the business arm of DOE IP.

- Coordinates sale and distribution of DOE isotope products and services available from DOE facilities.
- Contractual discussions with customers.
- Transportation, Q&A, public relations, marketing strategy and assessments.



- www.isotopes.gov
- Sign up here for DOE IP newsletter



Produce and/or distribute radioactive and stable isotopes that are in short supply; includes by-products, surplus materials and related isotope services



Maintain the infrastructure required to produce and supply priority isotope products and related services



Conduct R&D on new and improved isotope production and processing techniques which can make available priority isotopes for research and application. Develop workforce.



Ensure robust domestic supply chains. Reduce U.S. dependency on foreign supply to ensure National Preparedness.

The DOE IP does not compete with domestic industry and sells isotopes at market price or full-cost recovery ("non-profit"). Aid in commercialization of isotope when market is robust. Must be prepared to "step away" when market is stable.



DOE IP Authority, Resources, Goals

- Atomic Energy Acts of 1946 and 1954 established U.S. policy of promoting R&D of nuclear materials for peaceful & military purposes.
 - Peaceful purpose includes production and sale of isotopes not produced or reasonably available from domestic private industry.
- DOE IP Sole authority to produce isotopes for sale and distribution
 - Produce over 80 radioisotopes and provide over 240 stable isotopes
 - Labs may not embark on isotope production on their own
 - Sales through the National Isotope Development Center
 - Separate business arm of DOE IP.

** DOE IP is not responsible for Mo-99 (NNSA), Pu-238 for NASA (NE), Special Nuclear Materials (SNM) for weapons (NNSA).




Isotope Landscape – What are Stable Isotopes?

- Isotopes are atoms of a chemical element that have the same number of protons but different neutrons.
- Stable isotopes are found naturally and do not decay.
 - Enriched stable isotopes are used in a variety of applications as well as the production of radioisotopes.
 - Enrichment technologies include:
 - Distillation
 - Gas Centrifuge Isotope Separation (GCIS)
 - Electromagnetic Isotope Separation (EMIS)
 - Thermal Diffusion Isotope Separation (TDIS)
 - Atomic Vapor Laser Isotope Separation (AVLIS) R&D



Manhattan Project calutrons that enriched uranium via electromagnetic separation (defunct)




Piketon Plant gas centrifuges (defunct but capability being revived)



Isotope Landscape – What are Radioisotopes?

- Radioisotopes are unstable isotopes of a chemical element
 - Contain an unstable combination of neutrons and protons.
 - Decay to a lower energy daughter via alpha, beta, or gamma ray emission.
 - Occur naturally or are created in reactors, accelerators, and cyclotrons





Reactors

Accelerators





Examples: Alternative Isotope Production

Y-12 National Security Complex

- Includes production of Li-6 (neutron detection) and Li-7 (dosimeters)
- Demo of high purity isotopes for NG reactors





Pacific Northwest National Laboratory

• Sr-90 power sources (terrestrial and space), reduces foreign dependence

Los Alamos Plutonium Facility


 Am-241 from Pu waste streams (smoke detectors, power sources)


Savannah River Site (SRS)

 He-3 extraction from NNSA tritium (cryogenics, national security, neutron detection)




Isotope Landscape – Applications









Basic Research

Physics
'New Element
Discovery'
Chemistry
Materials
Quantum Computing
Analytical Chemistry
Geosciences

Medicine

Cancer Therapies
Imaging/Diagnostics
'Infectious Disease
Treatment'
Drug Development
'Medical Device
Calibration'
Research

Industry

Semi-conductors
Standards
Inspections
'Oil and Gas
Exploration'
Batteries
Pesticides
Food Sterilization

National Security

'Satellite
Communications'
Detection
Nuclear Batteries
'Global Positioning
Sources'
Quantum-encryption
Space Exploration



Isotope Landscape – U.S. Production History

1946 - 1985

U.S. production increased and then leveled out

1986 - 2000

Foreign producers take advantage of losses in U.S. production capabilities

2001 - 2008

U.S. production is limited, and imports most bulk isotopes used in industry, research, and medicine

2009 – Present

U.S. production increases with new capabilities. U.S. still dependent on foreign supply for critical isotopes. Periodic shortages occur.

- National Labs produce isotopes for research and industry.
- Calutrons
 converted from
 uranium to stable
 isotope enrichment.


- Research reactor capacity reduced.
- Radioisotope processing facilities shut down late 1980s
- Fall of USSR in 1991.
 Russia enters the market.
- U.S. calutrons shut down 1999

- U.S. relies on foreign sources for bulk isotopes.
- U.S. industry refines foreign-supplied isotopes into finished end-use products.
- 2003 DOE no longer supports isotope R&D and production.

- Isotope R&D and production restarts
- DOE IP sites & University
 Network added
- Increased radiochemical processing capabilities
- Restart enriched stable isotope production and core competencies.




DOE IP Growth – Production Sites in 2009



2009 – Program transferred to the Office of Science



DOE IP Growth – Production Sites in 2023




Green boxes

– under
development



DOE IP Growth – DOE IP Enacted Budget





DOE IP – Impact on Medical Isotopes

Available Medical Isotopes - isotopes in red made available within the past two years					
Ac-225/Bi-213	Br-77	Lu-177 c.a.	Rb-83	Ti-44	
Ac-227	Cd-109	Mn-52g	Rh-103m	V-48	
Al-26	Ce-134	Mn-54**	Se-72	W-188/Re-188	
As-73	Ce-139	Na-22	Se-75	Y-86	
At-211	Co-55	Pb-203	Sn-117m (HSA)	Y-88	
Au-199	Co-60 (HSA)	Pd-103	Sr-85	Yb-176	
Ba-133	Fe-52	Pm-147	Sr-89	Zn-65	
Be-7	Fe-55	Ra-223	Sr-90/Y-90		
Bi-207	He-3	Ra-224/Pb-212	Th-227		
Br-76**	lr-192	Ra-226	Th-228		

Medical Isotopes Under Development					
As-72 /Se-72	Gd-153	Ru-106	Ti-44/Sc-44		
C-14	Mo-98 &100	Sb-119	Xe-129		
Co-57	Nb-90	Sc-43, 44, & 47	U-230/Th226		
Cs-131	Pt-191,193m, & 195m	Tb-155 & 161			
Fe-59	Re-186 & 189 (HSA)	Te-119m/Sb-119			

R&D funded by DOE IP and executed through our National Laboratories,
Universities and other institutions is key to the program's success



DOE IP – Assessment of U.S. Critical Needs

- Industry: Commercial stakeholder meetings twice a year and annual Industrial Surveys
- Biennial Federal Workshops and 5-year surveys
- Sponsorship of workshops, symposiums at conferences
- White House Working Groups
- Inter-agency Working Groups
- Community Meetings and Round Tables
- Professional Society Meetings and Exhibit Booths





























NIS

















Johnson Johnson















SANDERS











































Status of U.S. Capabilities & DOE IP Priorities

- Key technical abilities and core competencies lost
- Limited resources to provide critical isotopes for the Nation
- Unacceptable risks with dependence on sensitive countries

Priorities:

- U.S. economic resilience
- Emerging technology
- Life-saving medical treatments
- Scientific strength
- National security

Increase Mission Readiness Increase isotope production core competencies

Increase radiochemical processing capabilities

Increase stable isotope inventory Increase stable isotope enrichment capabilities




DOE IP LIC Projects and Initiative Priorities

- Isotope projects and initiatives core element of long-term plans for expanding isotope production capabilities
 - Re-establish core capabilities in the U.S for producing and enriching key isotopes and remove dependence on foreign countries.
 - Russian invasion of Ukraine highlighted U.S. vulnerabilities for isotopes.
 - Essential to maintain domestic security, health, and economic resilience.
- Initiatives 'Projectized' critical R&D and operations to ensure deliverables within budget and schedule.
- Line-Item Construction Projects
 - Stable Isotope Production and Research Center SIPRC
 - Clinical Alpha Radionuclide Producer CARP
 - Radioisotope Processing Facility RPF



FRIB Isotope Harvesting Facility (DOE IP Initiative)





The Isotope Harvesting Project (\$13.2M) is a research initiative to enable harvesting of radioisotope from the FRIB beam dump. The effort will support the production of radioisotopes for research.

Conceptual and actual view of new hot cells for purifying and harvesting radioisotopes.





Stable Isotope Production and Research Center - \$325M

- Production-oriented new facility with EMIS and GC technologies.
 - Reestablishes large-scale stable isotope enrichment in the U.S.
 - Incorporates space for expansion.
- Scope includes pre-CD-1 planning activities and 3 subprojects:



External View - SIPRC

- Subproject 1 (SP1 Facility and EMIS
- Subproject 2 (SP2) Mo-100 Production Cascade
- Subproject 3 (SP3) Test Cascade Infrastructure



SIPRC Project


- CD-0 approved FY19
- CD-1 approved FY21
- CD-4: Q3 FY32 (Planned)
- Approved CD-1 TPC Range: \$187M to \$338M
- Current Total Point Estimate: \$325M
- FY22 IRA Funding: \$75M significant impact and schedule risk mitigation.

Subproject 1: Facility and EMIS

- SP1 CD-2/3 Approval: March 2024
- Baselined TPC and CD-4: \$231.5M, Q4 FY30


External View - SIPRC





Clinical Alpha Radionuclide Producer (CARP)

- Added capability to process accelerator-based radioisotopes at BLIP – Brookhaven Linac Isotope Producer.
- Hazard Category 3 (HC3) Nuclear Facility Repurposes an existing building at BNL (Bldg. 870). Relatively clean and operated as HC3 in the 80s.



Internal View – Bldg. 870

Scope:

- Modest building utility upgrades to bring it up to current HC3 requirements.
- Design, procurement, installation and commissioning of hot cells and radiochemical processing equipment and related support spaces.




- CD-0 approved December 2022
- CD-1 planned Q4 FY26
 - Constrained early funding
 - TEC start in FY24 Enacted Budget
- Approved CD-0 TPC Range: \$60M to \$80M

Proposed

Hot Cells

- CD-4: Q4 FY31 (Planned)
- Funding as of end of FY23 \$585k
- FY24 Funding \$1.5M OPC, \$1M TEC





Radioisotope Processing Facility

- Hazard Category 2 (HC-2) Nuclear facility
- New facility with up to eight processing bays
 - Multiple combination of Modular Hot Cells, gloveboxes, and other radiochemical processing equipment hood to meet production needs.
 - Includes space for supporting laboratories and R&D




External Rendering - RPF

- Reduce U.S. dependence on foreign suppliers; particularly Russia
- Expand research, production and processing capacity for high priority radioisotopes
- Focus on HFIR irradiated targets
- Incorporates expansion for the future

RPF@ORNL

- CD-0 approved April 2021
- CD-1 planned Q3 FY24 (TBD)
 - Constrained early funding
 - TEC start in FY24 Enacted Budget
- Approved CD-0 TPC Range: \$310M to \$615M



Internal View - RPF

- FY22 IRA Funding: \$10.6M Fully funded critical conceptual design activities
- CD-4: Q4 FY34 (Planned)

- Funding as of end of FY23 \$15.2M
- FY24 Funding –\$8.5M TEC

Summary

- Isotopes are enabling and foundational. Disruptions in supply can be crippling to industry, national security, federal missions, discovery research, emerging technology.
- Demand for radioisotopes and stable isotopes will only continue to quickly escalate.
- The U.S. has fallen significantly behind other world powers in its ability to produce isotopes. We lack the facilities and equipment, the core competencies, and the capabilities.
- DOE IP projects and initiatives that add needed capabilities are critical to the resilience of the U.S.



Thank You!



Questions?